Sotera Health Company (SHC)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 4
Bullish pullback-to-support: buy limit 18.95 near the SMA20/EMA21 support cluster (18.98/18.79) inside an uptrend above SMA20/50/200; protective stop 18.47 below the 09-15 swing low 18.56 (buffer 0.09, 1.04×ATR risk); targets 19.87 / 20.56 (2.0×/3.5× ATR14); R/R 1.92. No earnings or dividend events inside the 15-trading-day holding window (next confirmed earnings 2026-11-03, outside horizon 2026-10-07).
Company overview
Sotera Health Company provides sterilization, laboratory testing, and advisory services globally, with expertise in gamma and electron beam irradiation and ethylene oxide processing. Its Nelson Labs division offers microbiological and analytical chemistry analyses, serving sectors like medical devices, pharmaceuticals, and agriculture.
Fundamental
fairSotera Health shows strong margins and liquidity but faces litigation risks and leverage concerns.
Strong margins and improving recent earnings are supported by solid liquidity, but a leveraged balance sheet and ongoing EO litigation/regulatory exposure add meaningful tail risk. Valuation is not obviously cheap on earnings or free-cash-flow yield, and consensus targets imply limited upside near-term.
Sentiment
fairMedia sentiment has improved post-earnings, but litigation and insider selling remain concerns.
Post-Q2 earnings and a raised FY outlook (announced 2026-08-06) coincided with a clear improvement in media tone (last ~14d polarity_score ≈ +0.27 vs the 30–90d baseline ≈ -0.14), but insider-selling headlines and the persistent EO-litigation narrative keep the next-month setup two-sided; moderate red-flag cap applied (conflicting catalysts).
Technical
goodThe stock is in an uptrend above key moving averages, suggesting a pullback entry near support.
SHC closed 19.33 (+1.84%) on 2026-09-16, above all major moving averages (SMA20 18.98, SMA50 18.46, SMA200 16.89) and above its daily VWAP 19.30. EMA9 (18.82) > EMA21 (18.79) with price above WMA9/WMA21/DEMA14/TEMA14 confirms a short-term uptrend. Momentum is positive and improving: RSI14 59.87, Williams %R -22.81, MACD line +0.08 above zero with the histogram narrowing (-0.04 from -0.09). Volume confirms: 2.84M shares today vs ~1.8M recent average, with up-day volume exceeding down-day volume through the 4-session advance (18.26 → 19.33). Weak signals: ADX14 19.36 (<25; trend strength still developing inside a multi-month range) and overhead resistance at 19.63-19.85 (today's high / late-August highs / 52-week high). Rather than chase the breakout into that resistance, the plan is a limit entry at 18.95 — the SMA20/EMA21 support zone — within a trend-aligned pullback.
You’re looking at 2026-09-16 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.